EUVIMEDEUVIMED entdecken
Crossref

Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis

Huan Zhang, Jiayi Deng, Yang Liu, Wen Xia, Lulu Zhuang, Houan Zhou, Zhengzhao Liu, Haitao Zhang, Weixin Hu

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-025-07528-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Huan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Lupus Nephritis, Autoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Project of China, Jiangsu Biobank of Clinical Resources.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To explore the associations of novel serum autoantibodies with disease activity and organ injuries in patients with lupus nephritis (LN). METHOD: This study included 75 patients with active LN (5 class II, 37 class IV, and 33 class V). Indirect immunofluorescence was used to measure serum anti-dsDNA; ELISA was used to measure serum anti-PLA2R and anti-C1q, and the Luminex method was used to measure 58 novel serum autoantibodies, with a median fluorescence intensity (MFI)/threshold ≥ 1.5 as the antibody positivity cutoff. RESULTS: The positivity rates for 11 novel antibodies (anti-PLA2R, anti-P2RY11, anti-DEXI, anti-HARS, anti-TUBA1B, anti-KRT8, anti-TUBB, anti-NCL, anti-HSPB1, anti-AGRN, and anti-LGALS8) were highly associated with SLE activity and were inconsistent with those for anti-dsDNA and anti-C1q. Anti-TUBA1B and anti-AGRN positivity may independently influence LN with extrarenal organ involvement (OR = 6.73, 95% CI = 1.19 ~ 38.09; OR = 6.11, 95% CI = 1.32 ~ 28.25, respectively). The positivity rate for anti-PLA2R as detected by the Luminex platform was 40%, whereas the rate among those detected by ELISA was 12.7%. Twenty-one patients who achieved renal remission were retested, and the positivity rates of anti-PLA2R (42.9% vs. 9.5%, P = 0.014), anti-KRT8 (47.6% vs. 4.8%, P = 0.001), and anti-AGRN (38.1% vs. 4.8%, P = 0.008) also significantly decreased from baseline. CONCLUSION: On the basis of Luminex technology, the present study revealed multiple novel autoantibodies related to SLE activity and organ injury, especially anti-PLA2R, anti-KRT8, and anti-AGRN, thereby providing novel serological markers for the assessment of activity in patients with LN. Anti-TUBA1B and anti-AGRN are strongly associated with extrarenal involvement. Key Points • The Luminex method is highly sensitive and high-throughput for detecting serum autoantibodies. • LN patients with anti-TUBA1B and anti-AGRN positivity are more likely to be complicated by extrarenal organ involvement. • Serum anti-PLA2R, anti-KRT8, and anti-AGRN reflect the activity of SLE and provide novel serological markers for the evaluation of LN patients negative for anti-dsDNA and anti-C1q.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisAutoantibodiesHumansFemaleMaleAdultPilot ProjectsMiddle AgedEnzyme-Linked Immunosorbent AssayYoung AdultAntibodies, AntinuclearSeverity of Illness IndexFluorescent Antibody Technique, IndirectBiomarkers

Stichwörter der Autor:innen

AutoantibodiesLuminex technologyLupus nephritisOrgan injurySLE activitySystemic lupus erythematosus

Substanzen

AutoantibodiesAntibodies, AntinuclearBiomarkers

Autor:innen und Institutionen

  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.
  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. huwx0202@nju.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Project of China
  • Jiangsu Biobank of Clinical Resources

Zitieren

APA

Zhang, H., Deng, J., Liu, Y., Xia, W., Zhuang, L., Zhou, H., Liu, Z., Zhang, H., & Hu, W. (2025). Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07528-3

Vancouver

Zhang H, Deng J, Liu Y, Xia W, Zhuang L, Zhou H, et al. Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07528-3

BibTeX
@article{Zhang2025,
  author = {Zhang, Huan and Deng, Jiayi and Liu, Yang and Xia, Wen and Zhuang, Lulu and Zhou, Houan and Liu, Zhengzhao and Zhang, Haitao and Hu, Weixin},
  title = {Luminex-based pilot study identifies novel serum autoantibodies associated with disease activity in patients with lupus nephritis},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-025-07528-3}
}
Kostenlos starten →